WO2017021974A3 - Synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts - Google Patents

Synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts Download PDF

Info

Publication number
WO2017021974A3
WO2017021974A3 PCT/IN2015/000338 IN2015000338W WO2017021974A3 WO 2017021974 A3 WO2017021974 A3 WO 2017021974A3 IN 2015000338 W IN2015000338 W IN 2015000338W WO 2017021974 A3 WO2017021974 A3 WO 2017021974A3
Authority
WO
WIPO (PCT)
Prior art keywords
lysolecithin
lecithin
solubility
extracts
hydrophobic compounds
Prior art date
Application number
PCT/IN2015/000338
Other languages
French (fr)
Other versions
WO2017021974A8 (en
WO2017021974A2 (en
Inventor
Ganga Raju Gokaraju
Rama Raju Gokaraju
Kiran Bhupathiraju
Trimurtulu Golakoti
Ravichandran Sripathy
Nirvanashetty Somashekara
Ramchand Nanappan Chaniyilparampu
Original Assignee
Laila Pharmaceuticals Pvt. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laila Pharmaceuticals Pvt. Ltd. filed Critical Laila Pharmaceuticals Pvt. Ltd.
Priority to PCT/IN2015/000338 priority Critical patent/WO2017021974A2/en
Publication of WO2017021974A2 publication Critical patent/WO2017021974A2/en
Publication of WO2017021974A8 publication Critical patent/WO2017021974A8/en
Publication of WO2017021974A3 publication Critical patent/WO2017021974A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention discloses a composition(s) of hydrophobic plant molecule(s) and/or extract(s) with enhanced bioavailability comprising hydrophobic active and synergetic mixture of lecithin and lysolecithin and to the process for preparation thereof. More specifically, a composition for use in a therapeutic formulation, comprising: a synergistic mixture comprising from about 5% to about 25% of lecithin; and from about 75% to about 95% of lysolecithin, based on the combined weight of said lecithin and said lysolecithin; in combination with a hydrophobic active ingredient.
PCT/IN2015/000338 2015-08-31 2015-08-03 Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts WO2017021974A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2015/000338 WO2017021974A2 (en) 2015-08-31 2015-08-03 Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2015/000338 WO2017021974A2 (en) 2015-08-31 2015-08-03 Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts

Publications (3)

Publication Number Publication Date
WO2017021974A2 WO2017021974A2 (en) 2017-02-09
WO2017021974A8 WO2017021974A8 (en) 2018-03-08
WO2017021974A3 true WO2017021974A3 (en) 2019-01-17

Family

ID=57944200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000338 WO2017021974A2 (en) 2015-08-31 2015-08-03 Novel and synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts

Country Status (1)

Country Link
WO (1) WO2017021974A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018179011A1 (en) * 2017-03-29 2018-10-04 Olene Life Sciences Private Limited Composition to enhance bioavailability of natural compounds
CN110025604A (en) * 2019-04-11 2019-07-19 中国科学院西北高原生物研究所 Purposes of the hypericin in the Related product that preparation inhibits glucosidase activity
CN115813780A (en) * 2022-03-30 2023-03-21 广东格烯生物科技股份有限公司 Nano-scale yellow-dispelling composition containing tetrahydrocurcumin and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080145411A1 (en) * 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
US20090074942A1 (en) * 2005-05-17 2009-03-19 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
US20100137252A1 (en) * 2008-12-02 2010-06-03 Yasuko Matsumura Ophthalmic composition
US20110065662A1 (en) * 2009-07-24 2011-03-17 Amazentis Sa Compounds, Compositions, and Methods for Protecting Brain Health in Neurodegenerative Disorders
US20130337488A1 (en) * 2012-06-14 2013-12-19 Signpath Pharma Inc. Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite Tetrahydrocurcumin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074942A1 (en) * 2005-05-17 2009-03-19 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
US20080145411A1 (en) * 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
US20100137252A1 (en) * 2008-12-02 2010-06-03 Yasuko Matsumura Ophthalmic composition
US20110065662A1 (en) * 2009-07-24 2011-03-17 Amazentis Sa Compounds, Compositions, and Methods for Protecting Brain Health in Neurodegenerative Disorders
US20130337488A1 (en) * 2012-06-14 2013-12-19 Signpath Pharma Inc. Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite Tetrahydrocurcumin

Also Published As

Publication number Publication date
WO2017021974A8 (en) 2018-03-08
WO2017021974A2 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
MX344787B (en) Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders.
MX2017015879A (en) Hydroxypropyl beta-cyclodextrin compositions and methods.
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
BR112017009510A2 (en) compositions comprising cyclosporine
SG10201907291QA (en) Monomethylfumarate prodrug compositions
MX2017009289A (en) Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same.
PH12018502089A1 (en) Pharmaceutical composition of dapagliflozin
WO2017021974A3 (en) Synergistic composition of lecithin and lysolecithin for improving bioavailability and solubility of hydrophobic compounds and extracts
MY185605A (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2019012375A (en) Lfa-1 inhibitor formulations.
WO2016005962A3 (en) Stable liquid formulations of cyclophosphamide and processes
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
MX2018014790A (en) Combination formulation of three antiviral compounds.
PH12016501205A1 (en) Catecholamine production accelerator, and therapeutic and preventive agent and therapeutic and preventive food composition for diseases caused by catecholamine deficiency
PH12019500024A1 (en) Pharmaceutical compositions
GEP20196957B (en) Crystalline forms of s-acetyl glutathione, their reparations and uses in pharmaceutical and nutraceutical formulations
NZ702684A (en) Hexadepsipeptide analogues as anticancer compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15900306

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15900306

Country of ref document: EP

Kind code of ref document: A2